title: Outcome of medulloblastoma in children treated with reduced-dose radiation therapy plus adjuvant chemotherapy.
abstract: Medulloblastoma is the most common malignant brain tumor in children. Post-surgical craniospinal irradiation (CSI; 30-36 Gy) plus local boost radiation therapy (RT; 54-56 Gy) is a standard treatment for children with medulloblastoma who are over 3 years old, resulting in a 5-year overall survival (OS) rate of 46% to 65% in average-risk patients and 50% in high-risk patients. The addition of chemotherapy has the benefit of reducing complications from radiation and improving the OS rate. Using this approach, the estimated 5-year OS rates for patients with average- and high-risk medulloblastomas treated with different protocols are 65% to 85% and 16% to 70%, respectively. In this study, we determined the outcome of patients with average- and high-risk medulloblastomas treated with reduced dosage CSI and chemotherapy with an oral etoposide-based regimen. The study included 49 patients, with a mean age of 7.7 ± 3.4 years. Twenty-six patients (53%) were classified as average-risk and 23 patients (47%) as high-risk. In the average-risk group, the 5-year progression free survival (PFS) rate was 62.9% ± 10% and the 5-year OS rate was 70.4% ± 9.5%. In the high-risk group the 5-year PFS rate was 48.9% ± 13% and the 5-year OS rate was 49.7% ± 13%. In the average-risk group, patients who received CSI of either 24 Gy (n=20) or 36 Gy (n=9) showed no difference in their 5-year PFS and OS rates. We found that patients who were ≤ 10 years old and patients who were female had a significantly better 5-year PFS rate.
authors.affiliation: Department of Pediatrics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
authors.forename: Nongnuch
authors.initials: N
authors.lastname: Sirachainan
authors.forename: Issarang
authors.initials: I
authors.lastname: Nuchprayoon
authors.forename: Pattra
authors.initials: P
authors.lastname: Thanarattanakorn
authors.forename: Samart
authors.initials: S
authors.lastname: Pakakasama
authors.forename: Apasri
authors.initials: A
authors.lastname: Lusawat
authors.forename: Anannit
authors.initials: A
authors.lastname: Visudibhan
authors.forename: Mantana
authors.initials: M
authors.lastname: Dhanachai
authors.forename: Noppadol
authors.initials: N
authors.lastname: Larbcharoensub
authors.forename: Jiraporn
authors.initials: J
authors.lastname: Amornfa
authors.forename: Kanchana
authors.initials: K
authors.lastname: Shotelersuk
authors.forename: Kamornwan
authors.initials: K
authors.lastname: Katanyuwong
authors.forename: Saipin
authors.initials: S
authors.lastname: Tangkaratt
authors.forename: Suradej
authors.initials: S
authors.lastname: Hongeng
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002528:Cerebellar Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*; D017024:Chemotherapy, Adjuvant; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D016371:Cranial Irradiation / Q000379:methods; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008527:Medulloblastoma / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*; D011878:Radiotherapy; D011879:Radiotherapy Dosage; D016896:Treatment Outcome